Symbols

ENGN

enGene Holdings·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

Significant Net Income Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ENGN

Engene Holdings Inc.

A clinical-stage biotechnology company focused on non-viral gene therapies

Industry

Biological Technology

Established Date

04/24/2023

Listing Date

02/01/2022

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

10-31

Website

www.engene.com

Security Type

Common stock

Office address

4868 Rue Levy Suite 220 Saint-Laurent QC Canada H4R 2P1

Business

Introduction

EnGene Holdings Inc., was registered under the federal laws of Canada as 14963148 Canada Inc., on April 24, 2023, and changed its name to enGene Holdings Inc., on May 9, 2023. The company is a clinical-stage biotechnology company that brings genetic medicine into the mainstream by delivering therapeutic drugs to mucosal tissues and other organs, with the goal of creating new approaches to address diseases with high clinical needs, starting with non-muscle invasive bladder cancer (NMIBC). The company is developing non-viral gene therapies based on its novel and proprietary dual-derived chitosan or "DDX" gene delivery platform, which allows direct localized delivery of multiple gene cargoes to mucosal tissues and other organs.

Company Financials

EPS

ENGN has released its 2025 Q3 earnings. EPS was reported at -0.57, versus the expected -0.51, missing expectations. The chart below visualizes how ENGN has performed over recent quarters, highlighting trends in earnings surprises.